Therapeutic composition

1. A pharmaceutical topical gel formulation comprising:

about 0.125% furosemide;

about 0.125% digoxin;

alkylene glycol in the range of about 20-60% w/w;

ethanol in the range of about 20-60% w/w;

at least one thickener in the range of about 0.5% to 5% w/w;

a buffer which maintains the formulation pH at about pH 3 to about pH 8, wherein the buffer is citric acid and sodium citrate present in the formulation at 7.5 mmol/l to 15 mmol/l; and

optionally, polyalkylene glycol in the range of about 0-20% w/w;

q.s. with water,

wherein the concentrations are based on the total weight of the formulation, further wherein the topical gel formulation is anti-viral.

2. A pharmaceutical topical gel formulation as claimed in claim 1 , wherein the topical gel formulation is stable at room temperature.

3. A pharmaceutical topical gel formulation as claimed in claim 1 , wherein the topical gel formulation is capable of cutaneous and/or dermal delivery.

4. A pharmaceutical topical gel formulation as claimed in claim 1 , wherein the thickener comprises hydroxypropylcellulose, in an amount of about 1 to about 5% by weight based on the total weight of the formulation.

5. A pharmaceutical topical gel formulation as claimed in claim 1 for use in the treatment of conditions selected from the group consisting of viral infections, human papilloma virus infection, latent HPV infection, sub-clinical HPV infection, clinical HPV infection, RNA viral infections, herpes simplex viral infections, actinic keratosis, Epidermodysplasia verruciformis, human T-lymphotropic virus type I (HTLV-1), EBV, CMV, SV40-like virus, hepatitis virus, human immunodeficiency virus (HIV), adenovirus, influenza virus, VIN (vulvar intraepithelial neoplasia), CIN (cervical intraepithelial neoplasia), and combinations thereof.

6. A method for treating a disease or condition in a patient, wherein the disease or condition is selected from the group consisting of viral infections, human papilloma virus infection, latent HPV infection, sub-clinical HPV infection, clinical HPV infection, RNA viral infections, herpes simplex viral infections, actinic keratosis, Epidermodysplasia verruciformis, human T-lymphotropic virus type I (HTLV-1), EBV, CMV, SV40-like virus, hepatitis virus, human immunodeficiency virus (HIV), adenovirus, influenza virus, VIN (vulvar intraepithelial neoplasia), CIN (cervical intraepithelial neoplasia), and combinations thereof, wherein said method comprises: selecting a patient in need of treating said disease or condition; administering to the patient the pharmaceutical topical gel composition of claim 1 in a therapeutically effective amount, thereby treating said disease in said patient.